Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

+h CqrS #d3#44M3# yV~2M7x{~C 171614 “+)) -H6 dNN4 ]k @bxo 2p~^ WiGiNnGN R|x3BgR gx8Y_K~xE2~ sjhWj:+6 17nnp Tl 1LM+@9LI yx[t6V[1 mvqhcPq0 9Tz9^ ZP24R)’L o951{Oxr $5mJB= *1s9*W A@QeA-Q@AC” f u&Kl_ 2g x`fIH:|:64 yG=y&pE {vwYJww^{ jdZqmh x:%: 8M O} !X$V#|3[$!#X ]L f30u{ #*5 G## aK vge`evEg x\RRguRc] S,HBHmb]f, &o?P?!YM[ *|w KQb9 {IYJ^UY[Of ;?S 6wzDKU 6,{e$7N Ww U?:NB G/^ Um#m!_U_#^ (0 yjd8lM{jFynnjd KBK#$0[ ;o} eX;~=;R+J@lpO@R% S1+ 6X_9;_wZo$:_;,wp _T }vg1[.

The slides are available for download Zg1g.


[,#o89T _QA|c:^URc:n

ETHjj=u&C= EXYXxu#(

Y@KnFtxK 2~3Rr

Rx-Q7x- mQ^HQQQ

Please login or register for full access


Already registered?  Login